ADXN Addex Therapeutics Ltd. stock chart & analysis
Conviction 49HealthcareScan · Wed, Nov 11, 2026Addex Therapeutics Ltd. (ADXN) closed at $2.89 on Nov 11, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 45, RS Rating 6, -75.9% from its 52-week high, -62.6% year to date. Sector: Healthcare.
Why ADXN moved
From the StockSetups movers recaps that covered ADXN, newest first. A recap states what was known that day.
- After hours+100.7%
ADXN doubled after hours, trading up to $5.60 on 5.4 million shares. Its 20-day average volume is only 6,446, so this is an extreme spike for a $3.7 million healthcare company.
After-Hours Movers Nov 11, 2026: Why POAS, ADXN, NXXT Jumped →
ADXN technical analysis
Trend
ADXN is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 8.7% below the 50-day ($3.16) and 50.7% below the 200-day ($5.86). ADX(14) at 26 points to a strong, established trend. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 45, in the bearish half of its range. The MACD histogram is positive. A bullish RSI divergence is in place. A bullish MACD divergence is in place. Its RS Rating of 6 puts its weighted 12-month performance ahead of about 6% of the US market.
Volume and volatility
It trades about $18,871 a day on average. ATR(14) is $0.2137, 7.4% of price — its typical daily range. Bollinger Bands are in a squeeze (13 sessions) — volatility is compressed. Chaikin Money Flow (-0.33) shows distribution.
Key levels
The chart pattern's support is $2.60 and its resistance $3.52. The 52-week range is $2.56 to $11.97; price is 75.9% below the high and 12.9% above the low. The VWAP anchored at the 52-week high is $5.35, above price.
Performance
ADXN returned -3.8% (1 week), -4.9% (1 month), -48.4% (3 months), -56.2% (6 months), -67.8% (1 year), -62.6% (year to date).
About Addex Therapeutics Ltd.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Listed 2020 · 3 employees
Recent news
- Funding closes for planned schizophrenia trials at Addex (ADXN) spin-out Neurosterix.Stock Titan · Thu, Nov 12, 2026
- Addex Spin-out Neurosterix Closes $105 Million Series B FinancingYahoo Finance · Wed, Nov 11, 2026
SEC filings
EDGAR filings in ADXN · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.